Featured Products |
 |
 |
 |
 |
PERNIX THERAPEUTICS REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS
Posted on 05/10/2013
Revenues Increased 52% to $22.1 million compared to $14.5 million in the First Quarter 2012 Completed Acquisition of Somaxon in March 2013 Michael Pearce, Chairman of the Board, appointed President and Chief Executive Officer Cooper Collins appointed Chief Strategic Officer and remains on the Board of Directors For original press release including financial statements click [...]
» Continue Reading PERNIX THERAPEUTICS REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS
PERNIX THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2012 FINANCIAL RESULTS
Posted on 03/18/2013
Completed Acquisition of Cypress Pharmaceuticals and Hawthorn Pharmaceuticals Completed the Acquisition of Somaxon Pharmaceuticals in March 2013 Announced Plans to Launch Dr. Cocoa, an OTC Chocolate Flavored Cough & Cold Product Line For original release click <HERE> THE WOODLANDS, Texas, March 18, 2013 – Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NASDAQ: PTX), a [...]
» Continue Reading PERNIX THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2012 FINANCIAL RESULTS
Pernix Therapeutics Completes Acquisition of Somaxon Pharmaceuticals, Inc.
Posted on 03/07/2013
Pernix Therapeutics Completes Acquisition of Somaxon Pharmaceuticals, Inc. For original release click <HERE> THE WOODLANDS, TEXAS, March 6, 2012 – Pernix Therapeutics Holdings, Inc. (“Pernix”) (NASDAQ: PTX) today announced the completion of its acquisition of Somaxon Pharmaceuticals, Inc. (“Somaxon”) (NASDAQ: SOMX) following the approval of the transaction by stockholders of Somaxon at the special meeting [...]
» Continue Reading Pernix Therapeutics Completes Acquisition of Somaxon Pharmaceuticals, Inc.
Pernix Therapeutics to Report Fourth Quarter and Full Year 2012 Financial Results on March 18, 2013
Posted on 03/06/2013
For original press release click <HERE> Pernix Therapeutics to Report Fourth Quarter and Full Year 2012 Financial Results on March 18, 2013 Management to Host a Conference Call on March 18 at 9:00 a.m. EST THE WOODLANDS, Texas, March 5, 2013 – Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced that [...]
Pernix Therapeutics Receives FDA Approvals
Posted on 02/28/2013
For original press release click <HERE> VITUZ® Approved as a Prescription Treatment for Cough and Cold Symptoms Company Receives ANDA Approval for Mefenamic Acid THE WOODLANDS, TEXAS, February 28, 2013 – Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NASDAQ: PTX), a specialty pharmaceutical company, today announced that its subsidiary, Hawthorn Pharmaceuticals, Inc., has received [...]
» Continue Reading Pernix Therapeutics Receives FDA Approvals